Frontiers in Immunology (Sep 2021)
Evolution of Serum Acute-Phase Glycoproteins Assessed by 1H-NMR in HIV Elite Controllers
- Ana-Irene Malo,
- Joaquim Peraire,
- Joaquim Peraire,
- Joaquim Peraire,
- Joaquim Peraire,
- Ezequiel Ruiz-Mateos,
- Jenifer Masip,
- Jenifer Masip,
- Jenifer Masip,
- Núria Amigó,
- Núria Amigó,
- Núria Amigó,
- José Alcamí,
- José Alcamí,
- José Alcamí,
- Santiago Moreno,
- Santiago Moreno,
- Josefa Girona,
- Josefa Girona,
- Josefa Girona,
- Graciano García-Pardo,
- Graciano García-Pardo,
- Graciano García-Pardo,
- Rosaura Reig,
- Francesc Vidal,
- Francesc Vidal,
- Francesc Vidal,
- Francesc Vidal,
- Antoni Castro,
- Antoni Castro,
- Antoni Castro,
- Lluís Masana,
- Lluís Masana,
- Lluís Masana,
- Lluís Masana,
- Anna Rull,
- Anna Rull,
- Anna Rull,
- Anna Rull
Affiliations
- Ana-Irene Malo
- Vascular Medicine and Metabolism Unit, Hospital Universitari Sant Joan, Reus, Spain
- Joaquim Peraire
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Joaquim Peraire
- Infection and Immunity Research Group (INIM), Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
- Joaquim Peraire
- Universitat Rovira i Virgili, Tarragona, Spain
- Joaquim Peraire
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Ezequiel Ruiz-Mateos
- Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla-Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain
- Jenifer Masip
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Jenifer Masip
- Infection and Immunity Research Group (INIM), Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
- Jenifer Masip
- Universitat Rovira i Virgili, Tarragona, Spain
- Núria Amigó
- Universitat Rovira i Virgili, Tarragona, Spain
- Núria Amigó
- Biosfer Teslab, Reus, Spain
- Núria Amigó
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- José Alcamí
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- José Alcamí
- AIDS Immunopathogenesis Unit, Instituto de Salud Carlos III, Madrid, Spain
- José Alcamí
- 0HIV Unit, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi iSunyer (IDIBAPS), Barcelona, Spain
- Santiago Moreno
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Santiago Moreno
- 1Hospital Universitario Ramón y Cajal Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
- Josefa Girona
- Universitat Rovira i Virgili, Tarragona, Spain
- Josefa Girona
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Josefa Girona
- 2Research Unit on Lipids and Atherosclerosis, Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
- Graciano García-Pardo
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Graciano García-Pardo
- Infection and Immunity Research Group (INIM), Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
- Graciano García-Pardo
- Universitat Rovira i Virgili, Tarragona, Spain
- Rosaura Reig
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Francesc Vidal
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Francesc Vidal
- Infection and Immunity Research Group (INIM), Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
- Francesc Vidal
- Universitat Rovira i Virgili, Tarragona, Spain
- Francesc Vidal
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Antoni Castro
- Vascular Medicine and Metabolism Unit, Hospital Universitari Sant Joan, Reus, Spain
- Antoni Castro
- Universitat Rovira i Virgili, Tarragona, Spain
- Antoni Castro
- 2Research Unit on Lipids and Atherosclerosis, Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
- Lluís Masana
- Vascular Medicine and Metabolism Unit, Hospital Universitari Sant Joan, Reus, Spain
- Lluís Masana
- Universitat Rovira i Virgili, Tarragona, Spain
- Lluís Masana
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- Lluís Masana
- 2Research Unit on Lipids and Atherosclerosis, Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
- Anna Rull
- Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain
- Anna Rull
- Infection and Immunity Research Group (INIM), Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain
- Anna Rull
- Universitat Rovira i Virgili, Tarragona, Spain
- Anna Rull
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
- DOI
- https://doi.org/10.3389/fimmu.2021.730691
- Journal volume & issue
-
Vol. 12
Abstract
Elite controllers (ECs) are an exceptional group of people living with HIV (PLWH) who maintain undetectable viral loads (VLs) despite not being on antiretroviral therapy (ART). However, this phenotype is heterogeneous, with some of these subjects losing virological control over time. In this longitudinal retrospective study, serum acute-phase glycoprotein profile assessed by proton nuclear magnetic resonance (1H-NMR) was determined in 11 transient controllers (TCs) who spontaneously lost virological control and 11 persistent controllers (PCs) who persistently maintained virological control over time. Both PCs and TCs showed similar acute-phase glycoprotein profiles, even when TCs lost the virological control (GlycB, p = 0.824 and GlycA, p = 0.710), and the serum acute-phase glycoprotein signature in PCs did not differ from that in HIV-negative subjects (GlycB, p = 0.151 and GlycA, p = 0.243). Differences in serum glycoproteins A and B were significant only in ECs compared to HIV-typical progressors (TPs) with < 100 CD4+ T-cells (p < 0.001). 1H-NMR acute-phase glycoprotein profile does not distinguish TCs form PCs before the loss of viral control. ECs maintain a low-grade inflammatory state compared to TPs. PCs revealed a closer serum signature to HIV-negative subjects, reaffirming this phenotype as a closer model of functional control of HIV.
Keywords